Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 31.3% in January

Oruka Therapeutics, Inc. (NASDAQ:ORKA) saw a large decrease in short interest in January. As of January 15th, there was short interest totaling 5,241,278 shares, a decrease of 31.3% from the December 31st total of 7,626,531 shares. Based on an average daily trading volume, of 475,433 shares, the short-interest ratio is presently 11.0 days. Currently, 14.4% of the company’s stock are sold short. Currently, 14.4% of the company’s stock are sold short. Based on an average daily trading volume, of 475,433 shares, the short-interest ratio is presently 11.0 days.

Oruka Therapeutics Price Performance

ORKA stock traded up $0.07 during trading on Monday, hitting $34.30. 485,819 shares of the company traded hands, compared to its average volume of 497,419. Oruka Therapeutics has a 1 year low of $5.49 and a 1 year high of $36.51. The company has a market cap of $1.66 billion, a PE ratio of -18.05 and a beta of -0.39. The stock’s 50-day simple moving average is $31.02 and its 200 day simple moving average is $23.77.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.01. Research analysts expect that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Insider Buying and Selling

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $31.81, for a total value of $222,670.00. Following the completion of the sale, the insider owned 1,518 shares of the company’s stock, valued at approximately $48,287.58. This trade represents a 82.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 24.69% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Financial Enhancement Group LLC acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at about $631,000. B Group Inc. boosted its position in Oruka Therapeutics by 28.8% during the second quarter. B Group Inc. now owns 75,000 shares of the company’s stock worth $841,000 after purchasing an additional 16,785 shares in the last quarter. Geode Capital Management LLC grew its holdings in Oruka Therapeutics by 100.6% in the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock valued at $7,932,000 after purchasing an additional 354,821 shares during the period. Affinity Asset Advisors LLC grew its holdings in Oruka Therapeutics by 10.7% in the second quarter. Affinity Asset Advisors LLC now owns 603,479 shares of the company’s stock valued at $6,765,000 after purchasing an additional 58,117 shares during the period. Finally, Franklin Resources Inc. increased its position in shares of Oruka Therapeutics by 40.6% in the second quarter. Franklin Resources Inc. now owns 1,012,968 shares of the company’s stock valued at $11,355,000 after buying an additional 292,421 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ORKA. HC Wainwright cut their price objective on Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, October 27th. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Guggenheim initiated coverage on shares of Oruka Therapeutics in a report on Monday, October 27th. They issued a “buy” rating and a $60.00 price target on the stock. UBS Group initiated coverage on shares of Oruka Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.67.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.